Category: Baxter InternationalSyndicate content

China halts anti-dumping probe into EU, Japan dialysis kit makers

December 17, 2014 by MassDevice

China closes out an anti-dumoing probe into foreign dialysis kit makers including Fresenius, Nikkiso and Nipro.

China halts anti-dumping probe into EU, Japan dialysis kit makers

Baxter IV container recall is Class I

November 21, 2014 by Mark Hollmer

The FDA slaps a Class I recall label on Baxter International's pullback of tainted containers used to prepare intravenous medicines.

Baxter IV container recall is Class I

Baxter's (NYSE:BAX) recall of tainted containers used to prepare intravenous medicines is drawing heightened FDA scrutiny. The regulatory agency slapped a Class I label on the effort, its most serious designation.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Medtech's betting on the GOP in midterm elections

October 24, 2014 by Brian Johnson

A look at the top 10 politicial action committee donations shows that medtech is betting heavily on a GOP win in the midterm elections.

Medtech's betting on the GOP in midterm elections

The medical device industry is betting on a Republican sweep of the U.S. Congress during the 2014 mid term elections, according to a MassDevice.com analysis of donations made by the industry's 10 largest political action committees.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Medical products push Baxter profit above estimate

October 16, 2014 by MassDevice

Baxter's 3rd-quarter profits beat expectations, driven by its medical product business, but shares slide on a lowered earnings forecast.

Medical products push Baxter profit above estimate

(Reuters) - Medical device and drug maker Baxter (NYSE:BAX) reported a higher-than-expected quarterly profit, as sales in its medical products business continued to grow.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Baxter biopharm spinout Baxalta's R&D is Cambridge-bound

September 30, 2014 by Alex Soule

Baxter International confirmed Cambridge, Mass., as the new R&D hub for Baxalta, the planned spinout of its biopharmaceuticals business.

Baxter biopharm spinout Baxalta's R&D is Cambridge-bound

Baxter names its pharma spinout: Baxalta

September 11, 2014 by Arezu Sarvestani

Baxter's has 'high' hopes for its coming Baxalta spinout, which will get a full visual work-up before the company goes live mid-2015.

Baxter names its pharma spinout: Baxalta

Baxter (NYSE:BAX) crept a little closer to spinning out its biopharmaceuticals division into an independent entity by giving the company a name: Baxalta.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Failure of Medtronic's Symplicity-3 trial doesn't mean the end of renal denervation for hypertension | Medtech Wall Street news for the week of September 1, 2014

September 4, 2014 by MassDevice

Here's a look at some of the top Wall Street stories for medical device companies this week: Renal denervation isn't dead, despite Medtronic trial's failure; Baxter says HQ will stay in Illinois, stays coy on Boston plans; Private equity owners rebrand KCI, Systagenix, LifeCell as Acelity

Renal denervation isn't dead, despite Medtronic trial's failure

September 2, 2014 by Brad Perriello

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp